Comparison of the bioavailability of uridine in mice after either oral or parenteral administration
Tóm tắt
We compared the bioavailability of uridine (Urd) (350 and 3500 mg/kg) administered either as a single SC injection or by gavage, in male CD8F1 mice. Plasma samples were analyzed for Urd and uracil (Ura) using high-pressure liquid chromatography. After Urd (3500 mg/kg, SC), plasma Urd levels peaked at 4900 μM and then declined to pretreatment levels (< 10 μM) within 6h. Plasma Ura concentrations peaked at 1400 μM and then declined initially more slowly than Urd. After Urd (3500 mg/kg, PO) plasma levels of Urd were fairly constant (range 33–82 μM) for up to 8 h and had returned to pretreatment levels at 16 h. Plasma Ura concentrations paralleled Urd, but were approxximately ten-fold higher. Areas under the concentration-time curve for Urd showed that the bioavailability of Urd after PO administration was 7% of that after SC administration. After Urd (350 mg/kg, SC) Urd levels peaked at 210 μM returning to pretreatment levels within 2 h. Plasma Ura levels reached a peak with 300 μM and then declined initially more slowly than those of Urd. After Urd (350 mg/kg, PO) plasma Urd levels were not perturbed, although Ura levels peaked at 50 μM after which they declined and could no longer be detected at 4 h. These data indicate that (a) the bioavailability of Urd (350 or 3500 mg/kg) was lower when given PO than when it was administered by SC injection; and (b) Urd (3500 mg/kg) PO resulted in prolonged and relatively constant plasma Urd levels compared with Urd (3500 mg/kg) SC. These results suggest that Urd PO should be compared with parenterally administered Urd in attempts to increase the therapeutic index of 5-fluorouracil and of antimetabolite inhibitors of de novo pyrimidine biosynthesis.
Tài liệu tham khảo
Cadman E, Dix DE, Handschumacher RE (1978) Clinical, biological, and biochemical effects of pyrazofurin. Cancer Res 38:682
Chadwick M, Rogers WI (1972) The physiological disposition of 5-fluorouracil in mice bearing solid L1210 lymphocytic leukemia. Cancer Res 32:1045
Covey JM, Straw JA (1983) Nonlinear pharmacokinetics of thymidine, thymine, and fluorouracil and their kinetic interactions in normal dogs. Cancer Res 43:4587
Evans RM, Laskin JD, Hakala MT (1980) Assessment of growth limiting events caused by 5-fluorouracil. Cancer Res 40:4113
Farghali H, Novotny L, Ryba M, Berank J, Janku I (1984) Biochem Pharmacol 33:655
Gasser T, Moyer JD, Handshumacher RE (1981) Novel single-pass exchange of circulating uridine in rat liver. Science 213:776
Girot R, Hamet M, Perignon JL, Geusnu M, Fox RM, Cartier P, Durandy A, Griscelli C (1983) Cellular immune deficiency in two siblings with hereditary orotic aciduria. N Engl J Med 308:700
Heidelberger C (1974) Fluorinated pyrimidines and their nucleosides. In: Sartorelli AC, Johns DG (eds) Handbook of experimental pharmacology, vol 38, part 1: Antineoplastic and immunosuppressive agents. Springer, Berlin, Heidelberg New York, p 193
Houghton JA, Houghton PJ, Wooton RS (1979) Mechanisms of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine, and 5-fluoro-2′-deoxyuridine. Cancer Res 39:2406
Johnson RK (1977) Reversal of toxicity and antitumor activity of N-(phosphon-acetyl)-L-aspartate by uridine or carbamyl-DL-aspartate in vivo. Biochem Pharmacol 26:81
Karle JM, Anderson LW, Dietrick DD, Cysyk RL (1980) Determination of serum and plasma uridine levels in mice, rats, and humans by high-ressure liquid chromatography. Anal Biochem 109:41
Karle JM, Anderson LW, Cysyk RL (1984) Effect of plasma concentrations of uridine on pyrimidine biosynthesis in cultured L1210 cells. J Biol Chem 259:67
Klubes P, Cerna I (1983) Use of uridine rescue to enhance the antitumor selectivity of 5-fluorouracil. Cancer Res 43:3182
Krenitsky JA, Barclay M, Jaquez JA (1964) Specificity of mouse uridine phosphorylase. J Biol Chem 239:805
Leyva A, Van Groeningen CJ, Kraal I, Gall H, Peters GJ, Lankelma J, Pinedo HM (1984) Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity. Cancer Res 44:5928
Major PP, Egan E, Herrick D, Kufe DE (1982) 5-fluorouracil incorporation into DNA of human breast carcinoma cells. Cancer Res 42:3005
Martin DS, Stolfi RL, Sawyer RC, Spiegelman S, Young RC (1982) High-dose 5-fluororacil with delayed uridine “rescue” in mice. Cancer Res 42:3964
Maybaum J, Ullman B, Mandel HG, Day JL, Sadee W (1980) Regulation of RNA- and DNA-directed actions of 5-fluoropyrimidines in mouse T-lymphoma (S-49) cells. Cencer Res 40:4209
Monks A, Cysyk RL (1982) Uridine regulation by the isolated rat liver: perfusion with an artificial oxygen carrier. Am J Physiol 242:R465
Moyer JD, Oliver JT, Handshumacher RE (1981) Salvage of circulating pyrimidine nucleosides in the rat. Cancer Res 41:3010
Moyer JD, Malinowski N, Ayers O (1985) Salvage of circulating pyrimidine nucleosides by tissues of the mouse. J Biol Chem 260:2812
Novotny L, Farghali H, Ryba M, Janku I, Beranek J (1984) Structure-intestinal transport and structure-metabolism correlations of some potential cancerostatic pyrimidine nucleosides in isolated rat jejunum. Cancer Chemother Pharmacol 13:195
Perlow L, Ohnuma T, Andrejczuk A, Shafir M, Strauchen J, Holland JF (1985) Pharmacology and toxicology of a seven-day infusion of 1-β-D-arabinofuranosylcytosine plus uridine in dogs. Cancer Res 45:2572
Plagemann PGW, Wohhueter RM (1980) Permeation of nucleosides, nucleic acid bases and nucleotides in animal cells Curr Top Membr Transp 14:225
Shiotani T, Weber G (1981) Purification and properties of dihydrothymine dehydrogenase from rat liver. J Biol Chem 256:219
Sieber SM, Botkin CC, Leslie KA, Cooney DA (1980) Embryotoxicity in mice of phosphonacetyl-L-aspartic acid (PALA), a new antitumor agent. II. Studies on its mechanism and reversibility. Teratology 22:321
Swyryd EA, Seaver SS, Stark GR (1974) N-(Phosphonacetyl)-L-aspartate a potent transition state analog inhibitor of aspartate transcarbamylase, blocks proliferation of mammalian cells in culture. J Biol Chem 249:6945
Tsuboi KK, Edmunds HN, Kwong LK (1977) Selective inhibition of pyrimidine biosynthesis and effect on proliferative growth of colonic cancer cells. Cancer Res 37:3080
Wilkinson DS, Crumley J (1976) The mechanism of 5-fluorouridine toxicity in Novikoff hepatoma cells. Cancer Res 36:4032
Wilkinson DS, Crumley J (1977) Metabolism of 5-fluorouracil in sensitive and resistant Novikoff hepatoma cells. J Biol Chem 252:1051
Yngner T, Peterson I, Lewan L (1977) Metabolism of (5-3H)uridine in mouse and specificity for labelling of liver ribonucleic acid. Int J Biochem 8:395